Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc171_8, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 8 input genes in category / 54 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0003713 transcription coactivator activity 2.575E-12 1.390E-10 6.361E-10 1.390E-10 7 310
2 GO:0030374 nuclear receptor transcription coactivator activity 9.335E-12 2.520E-10 1.153E-9 5.041E-10 5 54
3 GO:0016922 nuclear receptor binding 1.747E-10 3.144E-9 1.439E-8 9.433E-9 4 25
4 GO:0046966 thyroid hormone receptor binding 4.340E-10 5.859E-9 2.681E-8 2.344E-8 4 31
5 GO:0030331 estrogen receptor binding 2.454E-9 2.217E-8 1.014E-7 1.325E-7 4 47
6 GO:0035257 nuclear hormone receptor binding 2.463E-9 2.217E-8 1.014E-7 1.330E-7 5 161
7 GO:0051427 hormone receptor binding 4.695E-9 3.622E-8 1.657E-7 2.536E-7 5 183
8 GO:0004402 histone acetyltransferase activity 6.693E-9 4.297E-8 1.966E-7 3.614E-7 4 60
9 GO:0061733 peptide-lysine-N-acetyltransferase activity 7.162E-9 4.297E-8 1.966E-7 3.867E-7 4 61
10 GO:0034212 peptide N-acetyltransferase activity 1.185E-8 6.398E-8 2.927E-7 6.398E-7 4 69
11 GO:0035258 steroid hormone receptor binding 3.335E-8 1.637E-7 7.490E-7 1.801E-6 4 89
12 GO:0008080 N-acetyltransferase activity 6.765E-8 3.044E-7 1.393E-6 3.653E-6 4 106
13 GO:0016410 N-acyltransferase activity 1.193E-7 4.755E-7 2.175E-6 6.441E-6 4 122
14 GO:0016407 acetyltransferase activity 1.233E-7 4.755E-7 2.175E-6 6.656E-6 4 123
15 GO:0033142 progesterone receptor binding 9.645E-7 3.472E-6 1.589E-5 5.208E-5 2 4
16 GO:0042974 retinoic acid receptor binding 1.067E-6 3.600E-6 1.647E-5 5.760E-5 3 51
17 GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups 1.245E-6 3.955E-6 1.810E-5 6.724E-5 4 219
18 GO:0030375 thyroid hormone receptor coactivator activity 1.607E-6 4.822E-6 2.206E-5 8.679E-5 2 5
19 GO:0016746 transferase activity, transferring acyl groups 2.356E-6 6.695E-6 3.063E-5 1.272E-4 4 257
20 GO:0042809 vitamin D receptor binding 2.180E-5 5.886E-5 2.693E-4 1.177E-3 2 17
21 GO:0042975 peroxisome proliferator activated receptor binding 2.740E-5 7.046E-5 3.224E-4 1.480E-3 2 19
22 GO:0046965 retinoid X receptor binding 3.699E-5 9.080E-5 4.154E-4 1.997E-3 2 22
23 GO:0017025 TBP-class protein binding 4.050E-5 9.510E-5 4.351E-4 2.187E-3 2 23
24 GO:0030546 receptor activator activity 9.501E-5 2.138E-4 9.781E-4 5.131E-3 2 35
25 GO:0050681 androgen receptor binding 1.308E-4 2.825E-4 1.292E-3 7.062E-3 2 41
26 GO:0030545 receptor regulator activity 2.029E-4 4.214E-4 1.928E-3 1.096E-2 2 51
27 GO:0001135 RNA polymerase II transcription regulator recruiting activity 8.572E-4 1.714E-3 7.845E-3 4.629E-2 1 2
28 GO:0047485 protein N-terminus binding 1.065E-3 2.053E-3 9.395E-3
5.750E-2
 2 117
29 GO:0036033 mediator complex binding 1.714E-3 3.085E-3 1.411E-2
9.255E-2
 1 4
30 GO:0050693 LBD domain binding 1.714E-3 3.085E-3 1.411E-2
9.255E-2
 1 4
31 GO:0001134 transcription regulator recruiting activity 2.142E-3 3.731E-3 1.707E-2
1.157E-1
 1 5
32 GO:0001162 RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding 4.280E-3 7.222E-3 3.304E-2
2.311E-1
 1 10
33 GO:0070182 DNA polymerase binding 5.561E-3 8.832E-3 4.041E-2
3.003E-1
 1 13
34 GO:0001161 intronic transcription regulatory region sequence-specific DNA binding 5.561E-3 8.832E-3 4.041E-2
3.003E-1
 1 13
35 GO:0044213 intronic transcription regulatory region DNA binding 5.987E-3 9.237E-3 4.227E-2
3.233E-1
 1 14
36 GO:0070577 lysine-acetylated histone binding 7.266E-3 1.090E-2 4.987E-2
3.924E-1
 1 17
37 GO:0035259 glucocorticoid receptor binding 8.118E-3 1.185E-2
5.421E-2
4.384E-1
 1 19
38 GO:0000978 RNA polymerase II proximal promoter sequence-specific DNA binding 1.062E-2 1.510E-2
6.907E-2
5.737E-1
 2 379
39 GO:0000987 proximal promoter sequence-specific DNA binding 1.167E-2 1.616E-2
7.392E-2
6.301E-1
 2 398
40 GO:0002039 p53 binding 3.046E-2 4.112E-2
1.881E-1
1.000E0
 1 72
41 GO:0031490 chromatin DNA binding 3.587E-2 4.724E-2
2.162E-1
1.000E0
 1 85
Show 36 more annotations

2: GO: Biological Process [Display Chart] 8 input genes in category / 438 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0030518 intracellular steroid hormone receptor signaling pathway 1.061E-9 4.649E-7 3.097E-6 4.649E-7 5 136
2 GO:0043401 steroid hormone mediated signaling pathway 5.579E-9 1.222E-6 8.138E-6 2.444E-6 5 189
3 GO:0030521 androgen receptor signaling pathway 9.361E-9 1.367E-6 9.103E-6 4.100E-6 4 65
4 GO:0009755 hormone-mediated signaling pathway 1.463E-8 1.602E-6 1.067E-5 6.406E-6 5 229
5 GO:0071383 cellular response to steroid hormone stimulus 4.769E-8 4.055E-6 2.701E-5 2.089E-5 5 290
6 GO:0030522 intracellular receptor signaling pathway 5.555E-8 4.055E-6 2.701E-5 2.433E-5 5 299
7 GO:0033145 positive regulation of intracellular steroid hormone receptor signaling pathway 6.895E-8 4.314E-6 2.874E-5 3.020E-5 3 21
8 GO:0016573 histone acetylation 3.315E-7 1.632E-5 1.087E-4 1.452E-4 4 157
9 GO:0018393 internal peptidyl-lysine acetylation 3.759E-7 1.632E-5 1.087E-4 1.646E-4 4 162
10 GO:0006475 internal protein amino acid acetylation 4.349E-7 1.632E-5 1.087E-4 1.905E-4 4 168
11 GO:0018394 peptidyl-lysine acetylation 4.454E-7 1.632E-5 1.087E-4 1.951E-4 4 169
12 GO:1904017 cellular response to Thyroglobulin triiodothyronine 4.843E-7 1.632E-5 1.087E-4 2.121E-4 2 3
13 GO:1904016 response to Thyroglobulin triiodothyronine 4.843E-7 1.632E-5 1.087E-4 2.121E-4 2 3
14 GO:0006473 protein acetylation 7.736E-7 2.286E-5 1.523E-4 3.388E-4 4 194
15 GO:2000273 positive regulation of signaling receptor activity 7.830E-7 2.286E-5 1.523E-4 3.430E-4 3 46
16 GO:0045925 positive regulation of female receptivity 9.684E-7 2.651E-5 1.766E-4 4.242E-4 2 4
17 GO:0043543 protein acylation 1.423E-6 3.667E-5 2.442E-4 6.233E-4 4 226
18 GO:0060744 mammary gland branching involved in thelarche 2.420E-6 5.300E-5 3.530E-4 1.060E-3 2 6
19 GO:0002154 thyroid hormone mediated signaling pathway 2.420E-6 5.300E-5 3.530E-4 1.060E-3 2 6
20 GO:0042695 thelarche 2.420E-6 5.300E-5 3.530E-4 1.060E-3 2 6
21 GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway 3.060E-6 6.383E-5 4.251E-4 1.340E-3 3 72
22 GO:0045924 regulation of female receptivity 5.804E-6 1.156E-4 7.697E-4 2.542E-3 2 9
23 GO:0046543 development of secondary female sexual characteristics 7.254E-6 1.381E-4 9.201E-4 3.177E-3 2 10
24 GO:0001892 embryonic placenta development 8.004E-6 1.461E-4 9.730E-4 3.506E-3 3 99
25 GO:0060180 female mating behavior 8.864E-6 1.553E-4 1.034E-3 3.882E-3 2 11
26 GO:0033148 positive regulation of intracellular estrogen receptor signaling pathway 1.063E-5 1.792E-4 1.193E-3 4.658E-3 2 12
27 GO:0045618 positive regulation of keratinocyte differentiation 1.257E-5 1.966E-4 1.309E-3 5.504E-3 2 13
28 GO:0045136 development of secondary sexual characteristics 1.257E-5 1.966E-4 1.309E-3 5.504E-3 2 13
29 GO:0018205 peptidyl-lysine modification 1.757E-5 2.654E-4 1.768E-3 7.696E-3 4 426
30 GO:0010469 regulation of signaling receptor activity 1.857E-5 2.710E-4 1.805E-3 8.131E-3 3 131
31 GO:0016570 histone modification 2.124E-5 3.000E-4 1.998E-3 9.301E-3 4 447
32 GO:0016569 covalent chromatin modification 2.418E-5 3.310E-4 2.204E-3 1.059E-2 4 462
33 GO:0048608 reproductive structure development 2.880E-5 3.718E-4 2.477E-3 1.261E-2 4 483
34 GO:0030879 mammary gland development 2.897E-5 3.718E-4 2.477E-3 1.269E-2 3 152
35 GO:0061458 reproductive system development 2.974E-5 3.718E-4 2.477E-3 1.303E-2 4 487
36 GO:0045606 positive regulation of epidermal cell differentiation 3.056E-5 3.718E-4 2.477E-3 1.339E-2 2 20
37 GO:0001890 placenta development 3.702E-5 4.382E-4 2.919E-3 1.621E-2 3 165
38 GO:0006367 transcription initiation from RNA polymerase II promoter 4.412E-5 5.086E-4 3.387E-3 1.933E-2 3 175
39 GO:0060713 labyrinthine layer morphogenesis 4.820E-5 5.414E-4 3.606E-3 2.111E-2 2 25
40 GO:0060444 branching involved in mammary gland duct morphogenesis 6.070E-5 6.344E-4 4.226E-3 2.659E-2 2 28
41 GO:0060669 embryonic placenta morphogenesis 6.070E-5 6.344E-4 4.226E-3 2.659E-2 2 28
42 GO:0007617 mating behavior 6.518E-5 6.344E-4 4.226E-3 2.855E-2 2 29
43 GO:0044705 multi-organism reproductive behavior 6.518E-5 6.344E-4 4.226E-3 2.855E-2 2 29
44 GO:0061384 heart trabecula morphogenesis 6.518E-5 6.344E-4 4.226E-3 2.855E-2 2 29
45 GO:0045616 regulation of keratinocyte differentiation 6.518E-5 6.344E-4 4.226E-3 2.855E-2 2 29
46 GO:0033146 regulation of intracellular estrogen receptor signaling pathway 7.958E-5 7.416E-4 4.939E-3 3.486E-2 2 32
47 GO:0045684 positive regulation of epidermis development 7.958E-5 7.416E-4 4.939E-3 3.486E-2 2 32
48 GO:0015721 bile acid and bile salt transport 8.469E-5 7.728E-4 5.148E-3 3.710E-2 2 33
49 GO:0006352 DNA-templated transcription, initiation 1.034E-4 9.240E-4 6.154E-3 4.527E-2 3 233
50 GO:0019098 reproductive behavior 1.249E-4 1.094E-3 7.289E-3
5.472E-2
 2 40
Show 45 more annotations

3: GO: Cellular Component [Display Chart] 8 input genes in category / 34 annotations before applied cutoff / 19061 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0090575 RNA polymerase II transcription factor complex 8.916E-6 3.031E-4 1.248E-3 3.031E-4 3 105
2 GO:0044798 nuclear transcription factor complex 1.854E-5 3.152E-4 1.298E-3 6.304E-4 3 134
3 GO:0016592 mediator complex 9.108E-5 1.032E-3 4.251E-3 3.097E-3 2 35
4 GO:0005667 transcription factor complex 3.719E-4 2.854E-3 1.175E-2 1.265E-2 3 368
5 GO:0005854 nascent polypeptide-associated complex 4.197E-4 2.854E-3 1.175E-2 1.427E-2 1 1
6 GO:0016591 RNA polymerase II, holoenzyme 7.180E-4 3.896E-3 1.604E-2 2.441E-2 2 98
7 GO:0000785 chromatin 8.435E-4 3.896E-3 1.604E-2 2.868E-2 3 487
8 GO:0000428 DNA-directed RNA polymerase complex 1.091E-3 3.896E-3 1.604E-2 3.711E-2 2 121
9 GO:0055029 nuclear DNA-directed RNA polymerase complex 1.091E-3 3.896E-3 1.604E-2 3.711E-2 2 121
10 GO:0030880 RNA polymerase complex 1.146E-3 3.896E-3 1.604E-2 3.896E-2 2 124
11 GO:0070847 core mediator complex 2.516E-3 7.776E-3 3.203E-2
8.554E-2
 1 6
12 GO:0061695 transferase complex, transferring phosphorus-containing groups 4.343E-3 1.231E-2
5.068E-2
1.477E-1
 2 244
13 GO:0000151 ubiquitin ligase complex 5.445E-3 1.424E-2
5.864E-2
1.851E-1
 2 274
14 GO:0000790 nuclear chromatin 7.537E-3 1.831E-2
7.538E-2
2.563E-1
 2 324
15 GO:0045120 pronucleus 8.782E-3 1.923E-2
7.919E-2
2.986E-1
 1 21
16 GO:0005680 anaphase-promoting complex 9.198E-3 1.923E-2
7.919E-2
3.127E-1
 1 22
17 GO:0005669 transcription factor TFIID complex 9.614E-3 1.923E-2
7.919E-2
3.269E-1
 1 23
18 GO:0071339 MLL1 complex 1.169E-2 2.093E-2
8.618E-2
3.976E-1
 1 28
19 GO:0044665 MLL1/2 complex 1.169E-2 2.093E-2
8.618E-2
3.976E-1
 1 28
20 GO:0048786 presynaptic active zone 1.543E-2 2.623E-2
1.080E-1
5.245E-1
 1 37
21 GO:0000152 nuclear ubiquitin ligase complex 1.750E-2 2.833E-2
1.167E-1
5.948E-1
 1 42
22 GO:0035097 histone methyltransferase complex 3.024E-2 4.673E-2
1.924E-1
1.000E0
 1 73
Show 17 more annotations

4: Human Phenotype [Display Chart] 1 input genes in category / 136 annotations before applied cutoff / 4707 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 HP:0040017 Protruding coccyx 4.249E-4 2.311E-2
1.270E-1
5.779E-2
 1 2
2 HP:0008472 Prominent protruding coccyx 4.249E-4 2.311E-2
1.270E-1
5.779E-2
 1 2
3 HP:0004696 Talipes cavus equinovarus 6.373E-4 2.311E-2
1.270E-1
8.668E-2
 1 3
4 HP:0009894 Thickened ears 8.498E-4 2.311E-2
1.270E-1
1.156E-1
 1 4
5 HP:0040016 Prominent coccyx 1.275E-3 2.311E-2
1.270E-1
1.734E-1
 1 6
6 HP:0200136 Oral-pharyngeal dysphagia 1.487E-3 2.311E-2
1.270E-1
2.023E-1
 1 7
7 HP:0008519 Abnormality of the coccyx 1.487E-3 2.311E-2
1.270E-1
2.023E-1
 1 7
8 HP:0011410 Caesarian section 1.700E-3 2.311E-2
1.270E-1
2.311E-1
 1 8
9 HP:0100797 Toenail dysplasia 1.700E-3 2.311E-2
1.270E-1
2.311E-1
 1 8
10 HP:0001304 Torsion dystonia 1.700E-3 2.311E-2
1.270E-1
2.311E-1
 1 8
11 HP:0006979 Sleep-wake cycle disturbance 1.912E-3 2.364E-2
1.299E-1
2.600E-1
 1 9
12 HP:0002548 Parkinsonism with favorable response to dopaminergic medication 2.974E-3 3.334E-2
1.831E-1
4.045E-1
 1 14
13 HP:0011822 Broad chin 3.187E-3 3.334E-2
1.831E-1
4.334E-1
 1 15
14 HP:0000437 Depressed nasal tip 4.886E-3 4.392E-2
2.413E-1
6.645E-1
 1 23
15 HP:0000579 Nasolacrimal duct obstruction 5.099E-3 4.392E-2
2.413E-1
6.934E-1
 1 24
16 HP:0001264 Spastic diplegia 5.736E-3 4.392E-2
2.413E-1
7.801E-1
 1 27
17 HP:0000308 Microretrognathia 6.798E-3 4.392E-2
2.413E-1
9.246E-1
 1 32
18 HP:0000391 Thickened helices 7.011E-3 4.392E-2
2.413E-1
9.535E-1
 1 33
19 HP:0011481 Abnormal lacrimal duct morphology 7.223E-3 4.392E-2
2.413E-1
9.824E-1
 1 34
20 HP:0001057 Aplasia cutis congenita 7.223E-3 4.392E-2
2.413E-1
9.824E-1
 1 34
21 HP:0002194 Delayed gross motor development 7.436E-3 4.392E-2
2.413E-1
1.000E0
 1 35
22 HP:0000336 Prominent supraorbital ridges 7.861E-3 4.392E-2
2.413E-1
1.000E0
 1 37
23 HP:0002141 Gait imbalance 8.073E-3 4.392E-2
2.413E-1
1.000E0
 1 38
24 HP:0000210 Micrognathia 8.073E-3 4.392E-2
2.413E-1
1.000E0
 1 38
25 HP:0100683 Abnormality of balance 8.073E-3 4.392E-2
2.413E-1
1.000E0
 1 38
Show 20 more annotations

5: Mouse Phenotype [Display Chart] 5 input genes in category / 466 annotations before applied cutoff / 10355 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 MP:0000628 abnormal mammary gland development 2.326E-7 1.084E-4 7.286E-4 1.084E-4 4 154
2 MP:0013554 abnormal apocrine gland morphology 1.790E-6 2.137E-4 1.437E-3 8.341E-4 4 256
3 MP:0000627 abnormal mammary gland morphology 1.790E-6 2.137E-4 1.437E-3 8.341E-4 4 256
4 MP:0000662 abnormal branching of the mammary ductal tree 1.834E-6 2.137E-4 1.437E-3 8.549E-4 3 60
5 MP:0009503 abnormal mammary gland duct morphology 3.912E-6 3.646E-4 2.451E-3 1.823E-3 3 77
6 MP:0009504 abnormal mammary gland epithelium morphology 6.483E-6 5.035E-4 3.385E-3 3.021E-3 3 91
7 MP:0003845 abnormal decidualization 1.694E-5 9.865E-4 6.632E-3 7.892E-3 2 14
8 MP:0010174 decreased mammary gland epithelial cell proliferation 1.694E-5 9.865E-4 6.632E-3 7.892E-3 2 14
9 MP:0010038 abnormal placenta physiology 4.472E-5 2.315E-3 1.557E-2 2.084E-2 3 173
10 MP:0005134 decreased thyroid-stimulating hormone level 5.127E-5 2.389E-3 1.606E-2 2.389E-2 2 24
11 MP:0010172 abnormal mammary gland epithelium physiology 7.016E-5 2.926E-3 1.967E-2 3.269E-2 2 28
12 MP:0005476 abnormal circulating triiodothyronine level 7.534E-5 2.926E-3 1.967E-2 3.511E-2 2 29
13 MP:0000279 ventricular hypoplasia 8.626E-5 3.092E-3 2.079E-2 4.020E-2 2 31
14 MP:0005472 abnormal triiodothyronine level 9.790E-5 3.259E-3 2.191E-2 4.562E-2 2 33
15 MP:0004014 abnormal uterine environment 1.302E-4 4.046E-3 2.720E-2
6.069E-2
 2 38
16 MP:0003971 abnormal thyroid-stimulating hormone level 1.671E-4 4.867E-3 3.272E-2
7.788E-2
 2 43
17 MP:0005183 abnormal circulating estradiol level 1.831E-4 5.020E-3 3.375E-2
8.535E-2
 2 45
18 MP:0003369 abnormal circulating estrogen level 2.174E-4 5.628E-3 3.783E-2
1.013E-1
 2 49
19 MP:0004264 abnormal extraembryonic tissue physiology 2.844E-4 6.975E-3 4.689E-2
1.325E-1
 3 322
20 MP:0005475 abnormal circulating thyroxine level 3.716E-4 8.658E-3
5.820E-2
1.732E-1
 2 64
21 MP:0005469 abnormal thyroxine level 4.704E-4 9.783E-3
6.577E-2
2.192E-1
 2 72
22 MP:0010927 decreased osteoid volume 4.829E-4 9.783E-3
6.577E-2
2.250E-1
 1 1
23 MP:0010930 decreased osteoid thickness 4.829E-4 9.783E-3
6.577E-2
2.250E-1
 1 1
24 MP:0005468 abnormal thyroid hormone level 5.952E-4 1.156E-2
7.769E-2
2.774E-1
 2 81
25 MP:0002652 thin myocardium 9.241E-4 1.689E-2
1.136E-1
4.306E-1
 2 101
26 MP:0010876 decreased bone volume 9.424E-4 1.689E-2
1.136E-1
4.392E-1
 2 102
27 MP:0013555 abnormal apocrine gland physiology 1.037E-3 1.725E-2
1.160E-1
4.830E-1
 2 107
28 MP:0001881 abnormal mammary gland physiology 1.037E-3 1.725E-2
1.160E-1
4.830E-1
 2 107
29 MP:0005669 increased circulating leptin level 1.389E-3 2.158E-2
1.451E-1
6.474E-1
 2 124
30 MP:0003972 decreased pituitary hormone level 1.389E-3 2.158E-2
1.451E-1
6.474E-1
 2 124
31 MP:0005312 pericardial effusion 1.742E-3 2.619E-2
1.761E-1
8.119E-1
 2 139
32 MP:0008253 absent megakaryocytes 1.930E-3 2.726E-2
1.832E-1
8.995E-1
 1 4
33 MP:0030482 increased osteocyte number 1.930E-3 2.726E-2
1.832E-1
8.995E-1
 1 4
34 MP:0001712 abnormal placenta development 2.106E-3 2.887E-2
1.941E-1
9.816E-1
 2 153
35 MP:0002189 abnormal myocardial trabeculae morphology 2.301E-3 3.064E-2
2.060E-1
1.000E0
 2 160
36 MP:0010874 abnormal bone volume 2.624E-3 3.343E-2
2.247E-1
1.000E0
 2 171
37 MP:0009661 abnormal pregnancy 2.654E-3 3.343E-2
2.247E-1
1.000E0
 2 172
38 MP:0006035 abnormal mitochondrion morphology 2.809E-3 3.372E-2
2.267E-1
1.000E0
 2 177
39 MP:0006372 impaired placental function 2.894E-3 3.372E-2
2.267E-1
1.000E0
 1 6
40 MP:0030481 abnormal osteocyte number 2.894E-3 3.372E-2
2.267E-1
1.000E0
 1 6
41 MP:0010928 abnormal osteoid thickness 3.376E-3 3.746E-2
2.518E-1
1.000E0
 1 7
42 MP:0010925 abnormal osteoid volume 3.376E-3 3.746E-2
2.518E-1
1.000E0
 1 7
43 MP:0010680 abnormal skin adnexa physiology 3.968E-3 4.301E-2
2.891E-1
1.000E0
 2 211
44 MP:0013559 abnormal exocrine gland physiology 4.269E-3 4.463E-2
3.000E-1
1.000E0
 2 219
45 MP:0009341 decreased splenocyte apoptosis 4.339E-3 4.463E-2
3.000E-1
1.000E0
 1 9
46 MP:0003965 abnormal pituitary hormone level 4.423E-3 4.463E-2
3.000E-1
1.000E0
 2 223
47 MP:0005667 abnormal circulating leptin level 4.502E-3 4.463E-2
3.000E-1
1.000E0
 2 225
48 MP:0001140 abnormal vagina epithelium morphology 4.820E-3 4.680E-2
3.146E-1
1.000E0
 1 10
Show 43 more annotations

6: Domain [Display Chart] 8 input genes in category / 61 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 IPR014935 SRC-1 InterPro 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
2 PF07469 DUF1518 Pfam 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
3 4.10.630.10 - Gene3D 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
4 IPR014920 Nuc rcpt coact Ncoa-typ InterPro 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
5 PF08832 SRC-1 Pfam 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
6 IPR008955 Src1 rcpt coact InterPro 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
7 IPR010011 DUF1518 InterPro 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
8 IPR017426 Nuclear rcpt coactivator InterPro 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
9 SM01151 DUF1518 SMART 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
10 PF08815 Nuc rec co-act Pfam 5.110E-11 3.117E-10 1.464E-9 3.117E-9 3 3
11 IPR009110 Nuc rcpt coact InterPro 1.021E-9 5.664E-9 2.660E-8 6.231E-8 3 6
12 PF00989 PAS Pfam 1.170E-7 5.491E-7 2.579E-6 7.138E-6 3 25
13 IPR013767 PAS fold InterPro 1.170E-7 5.491E-7 2.579E-6 7.138E-6 3 25
14 PF16279 DUF4927 Pfam 1.596E-7 6.488E-7 3.047E-6 9.733E-6 2 2
15 IPR032565 DUF4927 InterPro 1.596E-7 6.488E-7 3.047E-6 9.733E-6 2 2
16 SM00091 PAS SMART 2.520E-7 9.608E-7 4.512E-6 1.537E-5 3 32
17 PS50112 PAS PROSITE 3.039E-7 1.030E-6 4.837E-6 1.854E-5 3 34
18 IPR000014 PAS InterPro 3.039E-7 1.030E-6 4.837E-6 1.854E-5 3 34
19 4.10.280.10 - Gene3D 1.050E-5 3.372E-5 1.584E-4 6.407E-4 3 109
20 SM00353 HLH SMART 1.299E-5 3.791E-5 1.780E-4 7.926E-4 3 117
21 PS50888 BHLH PROSITE 1.333E-5 3.791E-5 1.780E-4 8.131E-4 3 118
22 IPR011598 bHLH dom InterPro 1.367E-5 3.791E-5 1.780E-4 8.339E-4 3 119
23 IPR028818 NCOA3 InterPro 4.270E-4 9.303E-4 4.369E-3 2.605E-2 1 1
24 IPR028822 NCOA2 InterPro 4.270E-4 9.303E-4 4.369E-3 2.605E-2 1 1
25 PF10744 Med1 Pfam 4.270E-4 9.303E-4 4.369E-3 2.605E-2 1 1
26 IPR019680 Mediator Med1 InterPro 4.270E-4 9.303E-4 4.369E-3 2.605E-2 1 1
27 IPR019258 Mediator Med4 InterPro 4.270E-4 9.303E-4 4.369E-3 2.605E-2 1 1
28 PF10018 Med4 Pfam 4.270E-4 9.303E-4 4.369E-3 2.605E-2 1 1
29 1.10.1100.10 - Gene3D 8.539E-4 1.532E-3 7.194E-3
5.209E-2
 1 2
30 IPR011177 TAF1 animal InterPro 8.539E-4 1.532E-3 7.194E-3
5.209E-2
 1 2
31 PF09247 TBP-binding Pfam 8.539E-4 1.532E-3 7.194E-3
5.209E-2
 1 2
32 PF12157 DUF3591 Pfam 8.539E-4 1.532E-3 7.194E-3
5.209E-2
 1 2
33 IPR009067 TAF II 230-bd InterPro 8.539E-4 1.532E-3 7.194E-3
5.209E-2
 1 2
34 IPR022591 TFIID sub1 DUF3591 InterPro 8.539E-4 1.532E-3 7.194E-3
5.209E-2
 1 2
35 PF00010 HLH Pfam 9.687E-4 1.688E-3 7.929E-3
5.909E-2
 2 112
36 IPR016641 EGD2/NACA InterPro 1.281E-3 2.170E-3 1.019E-2
7.811E-2
 1 3
37 SM01407 NAC SMART 2.133E-3 3.517E-3 1.652E-2
1.301E-1
 1 5
38 IPR002715 Nas poly-pep-assoc cplx dom InterPro 2.560E-3 3.903E-3 1.833E-2
1.561E-1
 1 6
39 PS51151 NAC AB PROSITE 2.560E-3 3.903E-3 1.833E-2
1.561E-1
 1 6
40 PF01849 NAC Pfam 2.560E-3 3.903E-3 1.833E-2
1.561E-1
 1 6
41 SM00086 PAC SMART 1.105E-2 1.568E-2
7.362E-2
6.741E-1
 1 26
42 IPR018359 Bromodomain CS InterPro 1.105E-2 1.568E-2
7.362E-2
6.741E-1
 1 26
43 IPR001610 PAC InterPro 1.105E-2 1.568E-2
7.362E-2
6.741E-1
 1 26
44 PS00633 BROMODOMAIN 1 PROSITE 1.569E-2 2.176E-2
1.022E-1
9.573E-1
 1 37
45 PF00439 Bromodomain Pfam 1.611E-2 2.184E-2
1.026E-1
9.830E-1
 1 38
46 PS50014 BROMODOMAIN 2 PROSITE 1.738E-2 2.216E-2
1.041E-1
1.000E0
 1 41
47 IPR001487 Bromodomain InterPro 1.780E-2 2.216E-2
1.041E-1
1.000E0
 1 42
48 SM00297 BROMO SMART 1.780E-2 2.216E-2
1.041E-1
1.000E0
 1 42
49 1.20.920.10 - Gene3D 1.780E-2 2.216E-2
1.041E-1
1.000E0
 1 42
50 PS50030 UBA PROSITE 1.990E-2 2.428E-2
1.140E-1
1.000E0
 1 47
Show 45 more annotations

7: Pathway [Display Chart] 7 input genes in category / 105 annotations before applied cutoff / 12450 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M13404 Control of Gene Expression by Vitamin D Receptor MSigDB C2 BIOCARTA (v6.0) 1.729E-11 1.815E-9 9.505E-9 1.815E-9 4 12
2 1270345 Transcriptional regulation of white adipocyte differentiation BioSystems: REACTOME 3.266E-10 1.715E-8 8.979E-8 3.430E-8 5 88
3 946598 Thyroid hormone signaling pathway BioSystems: KEGG 1.332E-9 4.428E-8 2.319E-7 1.399E-7 5 116
4 1270030 PPARA activates gene expression BioSystems: REACTOME 1.868E-9 4.428E-8 2.319E-7 1.962E-7 5 124
5 1270029 Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) BioSystems: REACTOME 2.109E-9 4.428E-8 2.319E-7 2.214E-7 5 127
6 M6907 Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells MSigDB C2 BIOCARTA (v6.0) 4.938E-8 8.642E-7 4.525E-6 5.185E-6 3 15
7 1270010 Fatty acid, triacylglycerol, and ketone body metabolism BioSystems: REACTOME 6.769E-8 1.015E-6 5.316E-6 7.107E-6 5 253
8 138039 Retinoic acid receptors-mediated signaling BioSystems: Pathway Interaction Database 2.490E-7 3.268E-6 1.711E-5 2.615E-5 3 25
9 1269873 RORA activates gene expression BioSystems: REACTOME 3.544E-7 4.135E-6 2.165E-5 3.722E-5 3 28
10 1269653 YAP1- and WWTR1 (TAZ)-stimulated gene expression BioSystems: REACTOME 3.952E-7 4.150E-6 2.173E-5 4.150E-5 3 29
11 1270039 Activation of gene expression by SREBF (SREBP) BioSystems: REACTOME 1.238E-6 1.182E-5 6.187E-5 1.300E-4 3 42
12 1268841 Transcriptional activation of mitochondrial biogenesis BioSystems: REACTOME 1.529E-6 1.338E-5 7.005E-5 1.605E-4 3 45
13 1269872 BMAL1:CLOCK,NPAS2 activates circadian gene expression BioSystems: REACTOME 1.862E-6 1.504E-5 7.876E-5 1.955E-4 3 48
14 1268839 Mitochondrial biogenesis BioSystems: REACTOME 2.667E-6 1.974E-5 1.034E-4 2.800E-4 3 54
15 1270038 Regulation of cholesterol biosynthesis by SREBP (SREBF) BioSystems: REACTOME 2.820E-6 1.974E-5 1.034E-4 2.961E-4 3 55
16 1269871 Circadian Clock BioSystems: REACTOME 6.120E-6 4.016E-5 2.103E-4 6.426E-4 3 71
17 SMP00383 Obesity / Metabolic Syndrome SMPDB 9.737E-6 6.014E-5 3.149E-4 1.022E-3 2 9
18 137975 RXR and RAR heterodimerization with other nuclear receptor BioSystems: Pathway Interaction Database 2.458E-5 1.434E-4 7.508E-4 2.581E-3 2 14
19 1270044 Synthesis of bile acids and bile salts via 27-hydroxycholesterol BioSystems: REACTOME 2.835E-5 1.567E-4 8.204E-4 2.977E-3 2 15
20 1270045 Recycling of bile acids and salts BioSystems: REACTOME 3.240E-5 1.701E-4 8.905E-4 3.402E-3 2 16
21 1270042 Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol BioSystems: REACTOME 7.435E-5 3.718E-4 1.947E-3 7.807E-3 2 24
22 1270192 Endogenous sterols BioSystems: REACTOME 1.017E-4 4.855E-4 2.542E-3 1.068E-2 2 28
23 1270041 Synthesis of bile acids and bile salts BioSystems: REACTOME 1.507E-4 6.881E-4 3.603E-3 1.583E-2 2 34
24 1270040 Bile acid and bile salt metabolism BioSystems: REACTOME 2.420E-4 1.059E-3 5.544E-3 2.541E-2 2 43
25 138027 Regulation of Androgen receptor activity BioSystems: Pathway Interaction Database 3.277E-4 1.376E-3 7.207E-3 3.441E-2 2 50
26 138085 Coregulation of Androgen receptor activity BioSystems: Pathway Interaction Database 4.262E-4 1.716E-3 8.985E-3 4.475E-2 2 57
27 M2404 Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) MSigDB C2 BIOCARTA (v6.0) 4.413E-4 1.716E-3 8.985E-3 4.633E-2 2 58
28 138045 HIF-1-alpha transcription factor network BioSystems: Pathway Interaction Database 5.542E-4 2.078E-3 1.088E-2
5.819E-2
 2 65
29 1270191 Cytochrome P450 - arranged by substrate type BioSystems: REACTOME 6.426E-4 2.299E-3 1.204E-2
6.747E-2
 2 70
30 1268838 Organelle biogenesis and maintenance BioSystems: REACTOME 6.568E-4 2.299E-3 1.204E-2
6.896E-2
 3 341
31 137963 Regulation of nuclear SMAD2/3 signaling BioSystems: Pathway Interaction Database 7.771E-4 2.632E-3 1.378E-2
8.160E-2
 2 77
32 138014 Glucocorticoid receptor regulatory network BioSystems: Pathway Interaction Database 8.808E-4 2.890E-3 1.513E-2
9.249E-2
 2 82
33 1404799 Endocrine resistance BioSystems: KEGG 1.205E-3 3.834E-3 2.007E-2
1.265E-1
 2 96
34 1270190 Phase 1 - Functionalization of compounds BioSystems: REACTOME 1.607E-3 4.962E-3 2.598E-2
1.687E-1
 2 111
35 1270435 HATs acetylate histones BioSystems: REACTOME 2.649E-3 7.833E-3 4.102E-2
2.782E-1
 2 143
36 1435207 Breast cancer BioSystems: KEGG 2.686E-3 7.833E-3 4.102E-2
2.820E-1
 2 144
37 1270189 Biological oxidations BioSystems: REACTOME 6.656E-3 1.889E-2
9.890E-2
6.989E-1
 2 229
38 M7968 Transcription Regulation by Methyltransferase of CARM1 MSigDB C2 BIOCARTA (v6.0) 7.288E-3 2.014E-2
1.054E-1
7.653E-1
 1 13
39 M8516 Multi-step Regulation of Transcription by Pitx2 MSigDB C2 BIOCARTA (v6.0) 8.405E-3 2.263E-2
1.185E-1
8.826E-1
 1 15
40 1270433 Chromatin organization BioSystems: REACTOME 9.755E-3 2.498E-2
1.308E-1
1.000E0
 2 279
41 1270434 Chromatin modifying enzymes BioSystems: REACTOME 9.755E-3 2.498E-2
1.308E-1
1.000E0
 2 279
42 1269843 Phosphorylation of the APC/C BioSystems: REACTOME 1.064E-2 2.597E-2
1.360E-1
1.000E0
 1 19
43 1269850 Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase BioSystems: REACTOME 1.064E-2 2.597E-2
1.360E-1
1.000E0
 1 19
44 1269762 Inactivation of APC/C via direct inhibition of the APC/C complex BioSystems: REACTOME 1.119E-2 2.612E-2
1.368E-1
1.000E0
 1 20
45 1269761 Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components BioSystems: REACTOME 1.119E-2 2.612E-2
1.368E-1
1.000E0
 1 20
46 1269758 Mitotic Spindle Checkpoint BioSystems: REACTOME 1.175E-2 2.682E-2
1.404E-1
1.000E0
 1 21
47 M5202 Hypoxia and p53 in the Cardiovascular system MSigDB C2 BIOCARTA (v6.0) 1.286E-2 2.814E-2
1.473E-1
1.000E0
 1 23
48 1269848 APC/C:Cdc20 mediated degradation of Cyclin B BioSystems: REACTOME 1.286E-2 2.814E-2
1.473E-1
1.000E0
 1 23
49 1269847 APC-Cdc20 mediated degradation of Nek2A BioSystems: REACTOME 1.398E-2 2.995E-2
1.568E-1
1.000E0
 1 25
50 M2499 CARM1 and Regulation of the Estrogen Receptor MSigDB C2 BIOCARTA (v6.0) 1.952E-2 4.099E-2
2.146E-1
1.000E0
 1 35
Show 45 more annotations

8: Pubmed [Display Chart] 8 input genes in category / 1418 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 12709428 The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. Pubmed 2.763E-14 1.959E-11 1.535E-10 3.918E-11 4 7
2 11117530 Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells. Pubmed 2.763E-14 1.959E-11 1.535E-10 3.918E-11 4 7
3 12082103 The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment. Pubmed 5.526E-14 2.612E-11 2.046E-10 7.836E-11 4 8
4 10882104 Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Pubmed 3.906E-13 1.333E-10 1.045E-9 5.539E-10 4 12
5 19255064 Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Pubmed 5.642E-13 1.333E-10 1.045E-9 8.000E-10 4 13
6 11266503 Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140. Pubmed 5.642E-13 1.333E-10 1.045E-9 8.000E-10 4 13
7 11500849 Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Pubmed 7.898E-13 1.600E-10 1.253E-9 1.120E-9 4 14
8 19183483 Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. Pubmed 1.877E-12 3.328E-10 2.607E-9 2.662E-9 4 17
9 11877444 T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. Pubmed 3.821E-12 4.276E-10 3.350E-9 5.418E-9 4 20
10 19596656 Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor. Pubmed 4.719E-12 4.276E-10 3.350E-9 6.692E-9 4 21
11 28390937 Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
12 12138202 The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
13 21035760 The transcriptional coregulators TIF2 and SRC-1 regulate energy homeostasis by modulating mitochondrial respiration in skeletal muscles. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
14 9506940 Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
15 21059860 Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
16 16423883 The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
17 16675958 Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
18 18845648 Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
19 23927929 Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
20 10501088 Structure and chromosomal locations of mouse steroid receptor coactivator gene family. Pubmed 6.031E-12 4.276E-10 3.350E-9 8.553E-9 3 3
21 24880616 Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action. Pubmed 1.383E-11 9.340E-10 7.317E-9 1.961E-8 4 27
22 26066330 miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
23 22560224 Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
24 15563453 Nuclear hormone receptor coregulator GRIP1 suppresses, whereas SRC1A and p/CIP coactivate, by domain-specific binding of MyoD. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
25 17854779 Ontogeny of steroid receptor coactivators in the hippocampus and their role in regulating postnatal HPA axis function. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
26 19095746 Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
27 15331759 Selective recruitment of p160 coactivators on glucocorticoid-regulated promoters in Schwann cells. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
28 18267973 P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
29 26267537 Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Pubmed 2.412E-11 1.180E-9 9.241E-9 3.421E-8 3 4
30 12514218 SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
31 10381882 Regulation of transcription by a protein methyltransferase. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
32 12796488 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
33 9812974 SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
34 10803578 Coactivator and corepressor gene expression in rat cerebellum during postnatal development and the effect of altered thyroid status. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
35 17476305 SIP, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasm. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
36 12714702 Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
37 10757795 The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
38 18511550 Dual role of the arginine methyltransferase CARM1 in the regulation of c-Fos target genes. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
39 17950690 Redundant enhancement of mouse constitutive androstane receptor transactivation by p160 coactivator family members. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
40 12554772 Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
41 15026545 A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
42 10652338 Transcription activation by the orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI). Definition of the domain involved in the glucocorticoid response of the phosphoenolpyruvate carboxykinase gene. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
43 18798693 Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
44 11376110 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Pubmed 6.030E-11 1.943E-9 1.523E-8 8.551E-8 3 5
45 11027271 Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Pubmed 1.206E-10 3.563E-9 2.791E-8 1.710E-7 3 6
46 16728408 Steroid receptor coactivator-3 is required for progesterone receptor trans-activation of target genes in response to gonadotropin-releasing hormone treatment of pituitary cells. Pubmed 1.206E-10 3.563E-9 2.791E-8 1.710E-7 3 6
47 16923966 Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly. Pubmed 1.206E-10 3.563E-9 2.791E-8 1.710E-7 3 6
48 12630920 Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. Pubmed 1.206E-10 3.563E-9 2.791E-8 1.710E-7 3 6
49 16860316 BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Pubmed 2.110E-10 5.697E-9 4.463E-8 2.992E-7 3 7
50 21195347 Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Pubmed 2.110E-10 5.697E-9 4.463E-8 2.992E-7 3 7
Show 45 more annotations

9: Interaction [Display Chart] 8 input genes in category / 762 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:NR1I3 NR1I3 interactions 2.216E-12 1.688E-9 1.218E-8 1.688E-9 5 39
2 int:VDR VDR interactions 3.339E-10 1.272E-7 9.176E-7 2.544E-7 5 103
3 int:FOS FOS interactions 5.016E-9 1.175E-6 8.477E-6 3.822E-6 5 176
4 int:PPARA PPARA interactions 6.226E-9 1.175E-6 8.477E-6 4.744E-6 4 56
5 int:KANK2 KANK2 interactions 7.710E-9 1.175E-6 8.477E-6 5.875E-6 4 59
6 int:THRB THRB interactions 2.408E-8 3.058E-6 2.206E-5 1.835E-5 4 78
7 int:THRA THRA interactions 4.502E-8 4.900E-6 3.535E-5 3.430E-5 4 91
8 int:JUN JUN interactions 6.791E-8 6.469E-6 4.666E-5 5.175E-5 5 296
9 int:NR4A1 NR4A1 interactions 1.042E-7 8.767E-6 6.324E-5 7.941E-5 4 112
10 int:AR AR interactions 1.151E-7 8.767E-6 6.324E-5 8.767E-5 5 329
11 int:NR5A2 NR5A2 interactions 1.974E-7 1.367E-5 9.864E-5 1.504E-4 3 28
12 int:RORA RORA interactions 2.201E-7 1.398E-5 1.008E-4 1.677E-4 3 29
13 int:SMARCE1 SMARCE1 interactions 2.559E-7 1.416E-5 1.021E-4 1.950E-4 4 140
14 int:ANKRD11 ANKRD11 interactions 2.707E-7 1.416E-5 1.021E-4 2.062E-4 3 31
15 int:RXRA RXRA interactions 2.787E-7 1.416E-5 1.021E-4 2.123E-4 4 143
16 int:PPARG PPARG interactions 3.951E-7 1.882E-5 1.358E-4 3.011E-4 4 156
17 int:NR2F1 NR2F1 interactions 4.673E-7 2.094E-5 1.511E-4 3.561E-4 3 37
18 int:NR1I2 NR1I2 interactions 5.938E-7 2.514E-5 1.813E-4 4.525E-4 3 40
19 int:RARA RARA interactions 6.554E-7 2.628E-5 1.896E-4 4.994E-4 4 177
20 int:ESRRB ESRRB interactions 7.010E-7 2.671E-5 1.927E-4 5.341E-4 4 180
21 int:TBP TBP interactions 7.992E-7 2.900E-5 2.092E-4 6.090E-4 4 186
22 int:PPARD PPARD interactions 1.572E-6 5.444E-5 3.927E-4 1.198E-3 3 55
23 int:NR1H2 NR1H2 interactions 1.946E-6 6.447E-5 4.651E-4 1.483E-3 3 59
24 int:AHR AHR interactions 2.375E-6 7.541E-5 5.440E-4 1.810E-3 3 63
25 int:YWHAH YWHAH interactions 2.478E-6 7.552E-5 5.448E-4 1.888E-3 4 247
26 int:NRIP1 NRIP1 interactions 3.269E-6 9.580E-5 6.911E-4 2.491E-3 3 70
27 int:NR3C1 NR3C1 interactions 3.428E-6 9.673E-5 6.978E-4 2.612E-3 4 268
28 int:PSMB9 PSMB9 interactions 3.560E-6 9.688E-5 6.989E-4 2.713E-3 3 72
29 int:STAT6 STAT6 interactions 3.712E-6 9.753E-5 7.036E-4 2.828E-3 3 73
30 int:PGR PGR interactions 4.713E-6 1.197E-4 8.636E-4 3.592E-3 3 79
31 int:NCOA6 NCOA6 interactions 5.880E-6 1.445E-4 1.043E-3 4.480E-3 3 85
32 int:MED26 MED26 interactions 6.754E-6 1.608E-4 1.160E-3 5.147E-3 3 89
33 int:HNF4A HNF4A interactions 6.986E-6 1.613E-4 1.164E-3 5.323E-3 3 90
34 int:NCOA2 NCOA2 interactions 7.712E-6 1.728E-4 1.247E-3 5.876E-3 3 93
35 int:MYOD1 MYOD1 interactions 8.754E-6 1.906E-4 1.375E-3 6.671E-3 3 97
36 int:GTF2B GTF2B interactions 1.080E-5 2.285E-4 1.649E-3 8.227E-3 3 104
37 int:CDK8 CDK8 interactions 1.349E-5 2.778E-4 2.004E-3 1.028E-2 3 112
38 int:NCOA1 NCOA1 interactions 1.499E-5 3.006E-4 2.168E-3 1.142E-2 3 116
39 int:CREBBP CREBBP interactions 1.640E-5 3.204E-4 2.312E-3 1.250E-2 4 398
40 int:CCND1 CCND1 interactions 1.787E-5 3.404E-4 2.456E-3 1.362E-2 3 123
41 int:CARM1 CARM1 interactions 2.158E-5 4.011E-4 2.894E-3 1.645E-2 3 131
42 int:NCOA3 NCOA3 interactions 3.367E-5 5.992E-4 4.323E-3 2.566E-2 3 152
43 int:HNF4G HNF4G interactions 3.381E-5 5.992E-4 4.323E-3 2.577E-2 2 20
44 int:TRIP4 TRIP4 interactions 4.460E-5 7.619E-4 5.496E-3 3.398E-2 3 167
45 int:TRIP11 TRIP11 interactions 4.500E-5 7.619E-4 5.496E-3 3.429E-2 2 23
46 int:NKX2-1 NKX2-1 interactions 5.215E-5 8.639E-4 6.232E-3 3.974E-2 3 176
47 int:SUMO1 SUMO1 interactions 5.763E-5 9.170E-4 6.615E-3 4.391E-2 3 182
48 int:ETV1 ETV1 interactions 5.776E-5 9.170E-4 6.615E-3 4.402E-2 2 26
49 int:RORB RORB interactions 6.237E-5 9.699E-4 6.997E-3 4.753E-2 2 27
50 int:MED13L MED13L interactions 7.211E-5 1.099E-3 7.928E-3
5.495E-2
 2 29
Show 45 more annotations

10: Cytoband [Display Chart] 8 input genes in category / 8 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 12q23-q24.1 12q23-q24.1 1.384E-3 1.012E-2 2.751E-2 1.107E-2 1 6
2 2p23 2p23 3.917E-3 1.012E-2 2.751E-2 3.134E-2 1 17
3 8q13.3 8q13.3 5.067E-3 1.012E-2 2.751E-2 4.054E-2 1 22
4 20q12 20q12 5.986E-3 1.012E-2 2.751E-2 4.789E-2 1 26
5 13q14.2 13q14.2 6.445E-3 1.012E-2 2.751E-2
5.156E-2
 1 28
6 12q24.11 12q24.11 7.592E-3 1.012E-2 2.751E-2
6.074E-2
 1 33
7 Xq13.1 Xq13.1 1.148E-2 1.312E-2 3.567E-2
9.187E-2
 1 50
8 17q12 17q12 2.398E-2 2.398E-2
6.518E-2
1.919E-1
 1 105
Show 3 more annotations

11: Transcription Factor Binding Site [Display Chart] 7 input genes in category / 31 annotations before applied cutoff / 9770 genes in category

No results to display

12: Gene Family [Display Chart] 7 input genes in category / 6 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 486 Basic helix-loop-helix proteins|Lysine acetyltransferases genenames.org 1.822E-11 1.093E-10 2.678E-10 1.093E-10 4 17
2 420 Basic helix-loop-helix proteins genenames.org 7.395E-6 2.218E-5 5.435E-5 4.437E-5 3 110
3 1061 Mediator complex genenames.org 6.662E-5 1.332E-4 3.264E-4 3.997E-4 2 33
4 402 Anaphase promoting complex |Tetratricopeptide repeat domain containing genenames.org 5.375E-3 8.062E-3 1.975E-2 3.225E-2 1 14
5 775 Myb/SANT domain containing|Trinucleotide repeat containing genenames.org 9.581E-3 1.150E-2 2.817E-2
5.748E-2
 1 25
6 769 Anaphase promoting complex |Tetratricopeptide repeat domain containing genenames.org 4.342E-2 4.342E-2
1.064E-1
2.605E-1
 1 115
Show 1 more annotation

13: Coexpression [Display Chart] 8 input genes in category / 735 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 15525570-SuppTable1 Human Ovarian Rae04 209genes GeneSigDB 3.008E-5 1.344E-2
9.644E-2
 2.211E-2 3 191
2 M672 Genes from common regions of gains observed in more than 15% of 148 primary breast cancer tumors. MSigDB C2: CGP Curated Gene Sets (v6.0) 3.656E-5 1.344E-2
9.644E-2
 2.687E-2 2 27
3 16254190-Table1 Mouse Skin Zhang05 51genes GeneSigDB 1.122E-4 2.749E-2
1.973E-1
8.248E-2
 2 47
4 14993899-TableS1 Human Futreal04 427genes ConsensusCancerGenes GeneSigDB 2.039E-4 2.843E-2
2.041E-1
1.499E-1
 3 364
5 18722011-SuppTable2j Human Leukemia Sanchez-Guijo08 77genes GeneSigDB 2.791E-4 2.843E-2
2.041E-1
2.051E-1
 2 74
6 16533764-Table3 Human Prostate Nadiminty06 110genes GeneSigDB 2.867E-4 2.843E-2
2.041E-1
2.107E-1
 2 75
7 M13522 Common down-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation. MSigDB C2: CGP Curated Gene Sets (v6.0) 4.682E-4 2.843E-2
2.041E-1
3.442E-1
 3 483
8 M12212 Down-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue. MSigDB C2: CGP Curated Gene Sets (v6.0) 5.193E-4 2.843E-2
2.041E-1
3.817E-1
 2 101
9 M19076 Genes up-regulated in metastatic breast cancer tumors having type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764] MSigDB C2: CGP Curated Gene Sets (v6.0) 7.198E-4 2.843E-2
2.041E-1
5.290E-1
 2 119
10 M1584 Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of v-MYB oncogenic varian of CMYB [GeneID=4602] off adenovirus vector. MSigDB C2: CGP Curated Gene Sets (v6.0) 8.191E-4 2.843E-2
2.041E-1
6.020E-1
 2 127
11 M3102 Genes up-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064]. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.080E-3 2.843E-2
2.041E-1
7.939E-1
 2 146
12 12747878-Table2 Human Breast Huang03 176genes LNmetastasis GeneSigDB 1.200E-3 2.843E-2
2.041E-1
8.823E-1
 2 154
13 M5659 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from patients with acute E. coli infection versus PBMC from patients with acute S. aureus infection. MSigDB C7: Immunologic Signatures (v6.0) 1.295E-3 2.843E-2
2.041E-1
9.517E-1
 2 160
14 M15066 Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.376E-3 2.843E-2
2.041E-1
1.000E0
 2 165
15 M6851 Genes up-regulated in spleens from mice immunized with ova peptides alone versus those immunized with LPS as adjuvant. MSigDB C7: Immunologic Signatures (v6.0) 1.393E-3 2.843E-2
2.041E-1
1.000E0
 2 166
16 M5657 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from patients with acute influenza infection versus PBMC from patients with acute S. pneumoniae infection. MSigDB C7: Immunologic Signatures (v6.0) 1.443E-3 2.843E-2
2.041E-1
1.000E0
 2 169
17 M5655 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from patients with acute influenza infection versus PBMC from patients with acute S. aureus infection. MSigDB C7: Immunologic Signatures (v6.0) 1.477E-3 2.843E-2
2.041E-1
1.000E0
 2 171
18 M6340 Genes up-regulated in Vd2 gamma delta T cells: untreated versus phorbol myristate acetate and ionomycin [PubChem=4792;3733]. MSigDB C7: Immunologic Signatures (v6.0) 1.511E-3 2.843E-2
2.041E-1
1.000E0
 2 173
19 M2038 Genes up-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.581E-3 2.843E-2
2.041E-1
1.000E0
 2 177
20 M8662 Genes down-regulated in bone marrow-derived macrophages: untreated versus stimulated by IFNG [GeneID=3458]. MSigDB C7: Immunologic Signatures (v6.0) 1.652E-3 2.843E-2
2.041E-1
1.000E0
 2 181
21 16449976-SuppTable2 Human Esophagus Wang06 245genes GeneSigDB 1.762E-3 2.843E-2
2.041E-1
1.000E0
 2 187
22 M2317 Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and down-regulated by its transcriptionally repressing form. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.894E-3 2.843E-2
2.041E-1
1.000E0
 2 194
23 M9824 Genes down-regulated in CD40L and IL-2 IL-4 IL-5 stimulated at day 3 B cell IRF4-KO versus CD40L and IL-2 IL-4 IL-5 stimulated at day 3 B cell wildtype. MSigDB C7: Immunologic Signatures (v6.0) 1.933E-3 2.843E-2
2.041E-1
1.000E0
 2 196
24 M8624 Genes down-regulated in bone marrow-derived dendritic cells CSF2 [GeneID=1437] versus CSF2 [GeneID=1437] and high dose of 1,3-beta-D-oligoglucan [PubChem=11375554]. MSigDB C7: Immunologic Signatures (v6.0) 1.933E-3 2.843E-2
2.041E-1
1.000E0
 2 196
25 M3487 Genes up-regulated in naive CD4 [GeneID=920] T cells from adult blood versus thymic stromal cells. MSigDB C7: Immunologic Signatures (v6.0) 1.972E-3 2.843E-2
2.041E-1
1.000E0
 2 198
26 M5136 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from healthy donors versus PBMCs from infanct with acute RSV infection. MSigDB C7: Immunologic Signatures (v6.0) 1.972E-3 2.843E-2
2.041E-1
1.000E0
 2 198
27 M4714 Genes up-regulated in comparison of dendritic cells (DC) stimulated with R848 at 2 h versus DCs stimulated with LPS (TLR4 agonist) and R848 for 2 h. MSigDB C7: Immunologic Signatures (v6.0) 1.992E-3 2.843E-2
2.041E-1
1.000E0
 2 199
28 M5753 Genes up-regulated in comparison of control RAW264.7 cells (macrophages) versus those infected with B. abortus. MSigDB C7: Immunologic Signatures (v6.0) 1.992E-3 2.843E-2
2.041E-1
1.000E0
 2 199
29 M4058 Genes up-regulated in comparison of dendritic cells (DC) stimulated with LPS (TLR4 agonist) at 12 h versus DC cells stimulated with Gardiquimod (TLR7 agonist) at 12 h. MSigDB C7: Immunologic Signatures (v6.0) 1.992E-3 2.843E-2
2.041E-1
1.000E0
 2 199
30 M4031 Genes up-regulated in comparison of dendritic cells (DC) stimulated with poly(I:C) (TLR3 agonist) at 16 h versus DC cells stimulated with Gardiquimod (TLR7 agonist) at 16 h. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
31 M3648 Genes up-regulated in comparison of unstimulated CD8 T cells at 72 h versus CD8 T cells at 72 h after treatment with trichostatin A (TSA) [PubChem=5562]. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
32 M9352 Genes down-regulated in follicular B lymphocytes versus marginal zone B cells. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
33 M3377 Genes down-regulated in comparison of Th1 cells versus naive CD4 [GeneID=920] T cells. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
34 M6044 Genes up-regulated in CD4 [GeneID=920] T cells: untreated (0h) versus activated by anti-CD3 and anti-CD28 and then stimulated by IL-12 (48h). MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
35 M8636 Genes up-regulated in bone marrow-derived dendritic cells: high dose of 1,3-beta-D-oligoglucan [PubChem=11375554] versus CSF2 [GeneID=1437] and high dose of 1,3-beta-D-oligoglucan [PubChem=11375554]. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
36 M8653 Genes up-regulated in P14 CD8+ T cells: ST2 [GeneID=6761] knockout versus wildtype. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
37 M9895 Genes up-regulated in dendritic cells: untreated versus 24h after infection of Leishmania major. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
38 M3707 Genes up-regulated in comparison of control dendritic cells (DC) at 1 h versus those stimulated with poly(I:C) (TLR3 agonist) at 1 h. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
39 M3948 Genes up-regulated in comparison of dendritic cells (DC) stimulated with poly(I:C) (TLR3 agonist) at 12 h versus DC cells stimulated with CpG DNA (TLR9 agonist) at 12 h. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
40 M3374 Genes down-regulated in comparison of Th1 cells versus Th17 cells. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
41 M299 Genes up-regulated in primary bronchial epithelial cells stimulated with: IL22 [GeneID=50616] versus IL17A [GeneID=3605]. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
42 M3365 Genes down-regulated in comparison of Th2 cells versus naive CD4 [GeneID=620] T cells. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
43 M7607 Genes down-regulated in CD11b+ cells from BALB/c mice bearing: C26GM colon carcinoma versus 4T1 mammary carcinoma. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
44 M5774 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from healthy donors versus PBMCs from patients with type 1 diabetes at the time of diagnosis. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
45 M8026 Genes up-regulated in macrophages (12h): rosiglitazone [PubChem=77999] and IL4 [GeneID=3565] versus IL4 [GeneID=3565]. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
46 M6745 Genes down-regulated in cells from Flt3L Melanom injected mice: 33D1+ versus B lymphocytes. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
47 M3203 Genes up-regulated in comparison of pre-germinal center B cells versus dark zone germinal center B cells. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
48 M6021 Genes down-regulated in CD4 [GeneID=920] T cells: untreated (0h) versus activated by anti-CD3 and anti-CD28 and then stimulated by IL4 [GeneID=3565] (6h). MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
49 M9133 Genes down-regulated in T reg: GATA1 [GeneID=2623] knockout versus wildtype. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
50 M6839 Genes up-regulated in CD4 [GeneID=920] T cells from lymph nodes: naïve versus day 28 after immunization. MSigDB C7: Immunologic Signatures (v6.0) 2.012E-3 2.843E-2
2.041E-1
1.000E0
 2 200
Show 45 more annotations

14: Coexpression Atlas [Display Chart] 8 input genes in category / 611 annotations before applied cutoff / 21829 genes in category

No results to display

15: Computational [Display Chart] 6 input genes in category / 65 annotations before applied cutoff / 10037 genes in category

No results to display

16: MicroRNA [Display Chart] 8 input genes in category / 560 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 hsa-miR-137:Non-Functional MTI Non-Functional MTI miRTarbase 4.683E-7 2.622E-4 1.811E-3 2.622E-4 3 148
2 hsa-miR-489:PITA hsa-miR-489:PITA TOP PITA 1.025E-6 2.870E-4 1.982E-3 5.739E-4 3 192
3 hsa-miR-513b:PITA hsa-miR-513b:PITA TOP PITA 4.877E-6 8.316E-4 5.743E-3 2.731E-3 3 323
4 hsa-miR-499-3p:PITA hsa-miR-499-3p:PITA TOP PITA 5.940E-6 8.316E-4 5.743E-3 3.327E-3 3 345
5 hsa-miR-33b-5p:TargetScan hsa-miR-33b-5p TargetScan 9.174E-6 8.562E-4 5.913E-3 5.137E-3 3 399
6 hsa-miR-33a-5p:TargetScan hsa-miR-33a-5p TargetScan 9.174E-6 8.562E-4 5.913E-3 5.137E-3 3 399
7 hsa-miR-647:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.768E-5 1.415E-3 9.769E-3 9.902E-3 2 58
8 hsa-miR-502-5p:PITA hsa-miR-502-5p:PITA TOP PITA 8.661E-5 5.819E-3 4.018E-2 4.850E-2 2 128
9 hsa-miR-1275:PITA hsa-miR-1275:PITA TOP PITA 9.351E-5 5.819E-3 4.018E-2
5.237E-2
 2 133
10 hsa-miR-17-3p:Functional MTI Functional MTI miRTarbase 1.581E-4 8.238E-3
5.689E-2
8.856E-2
 2 173
11 hsa-miR-647:PITA hsa-miR-647:PITA TOP PITA 1.618E-4 8.238E-3
5.689E-2
9.062E-2
 2 175
12 hsa-miR-425*:mirSVR highEffct hsa-miR-425*:mirSVR nonconserved highEffect-0.5 MicroRNA.org 1.867E-4 8.644E-3
5.969E-2
1.045E-1
 2 188
13 hsa-miR-188-3p:PITA hsa-miR-188-3p:PITA TOP PITA 2.742E-4 8.644E-3
5.969E-2
1.536E-1
 2 228
14 hsa-miR-18b-5p:TargetScan hsa-miR-18b-5p TargetScan 2.766E-4 8.644E-3
5.969E-2
1.549E-1
 2 229
15 hsa-miR-18a-5p:TargetScan hsa-miR-18a-5p TargetScan 2.766E-4 8.644E-3
5.969E-2
1.549E-1
 2 229
16 hsa-miR-433:PITA hsa-miR-433:PITA TOP PITA 3.165E-4 8.644E-3
5.969E-2
1.772E-1
 2 245
17 hsa-miR-659:PITA hsa-miR-659:PITA TOP PITA 3.268E-4 8.644E-3
5.969E-2
1.830E-1
 2 249
18 hsa-miR-298:PITA hsa-miR-298:PITA TOP PITA 3.811E-4 8.644E-3
5.969E-2
2.134E-1
 2 269
19 hsa-miR-1253:PITA hsa-miR-1253:PITA TOP PITA 4.011E-4 8.644E-3
5.969E-2
2.246E-1
 2 276
20 hsa-miR-205:PITA hsa-miR-205:PITA TOP PITA 4.127E-4 8.644E-3
5.969E-2
2.311E-1
 2 280
21 ACATTCC,MIR-206:MSigDB ACATTCC,MIR-206:MSigDB MSigDB 4.216E-4 8.644E-3
5.969E-2
2.361E-1
 2 283
22 ACATTCC,MIR-1:MSigDB ACATTCC,MIR-1:MSigDB MSigDB 4.216E-4 8.644E-3
5.969E-2
2.361E-1
 2 283
23 hsa-miR-140-5p:PITA hsa-miR-140-5p:PITA TOP PITA 4.216E-4 8.644E-3
5.969E-2
2.361E-1
 2 283
24 hsa-miR-507:PITA hsa-miR-507:PITA TOP PITA 4.860E-4 8.644E-3
5.969E-2
2.722E-1
 2 304
25 hsa-miR-557:PITA hsa-miR-557:PITA TOP PITA 4.860E-4 8.644E-3
5.969E-2
2.722E-1
 2 304
26 hsa-miR-515-5p:PITA hsa-miR-515-5p:PITA TOP PITA 5.282E-4 8.644E-3
5.969E-2
2.958E-1
 2 317
27 hsa-miR-580:PITA hsa-miR-580:PITA TOP PITA 5.516E-4 8.644E-3
5.969E-2
3.089E-1
 2 324
28 hsa-miR-219a-5p:TargetScan hsa-miR-219a-5p TargetScan 5.859E-4 8.644E-3
5.969E-2
3.281E-1
 2 334
29 hsa-miR-578:PITA hsa-miR-578:PITA TOP PITA 5.964E-4 8.644E-3
5.969E-2
3.340E-1
 2 337
30 hsa-miR-361-3p:mirSVR highEffct hsa-miR-361-3p:mirSVR nonconserved highEffect-0.5 MicroRNA.org 6.284E-4 8.644E-3
5.969E-2
3.519E-1
 2 346
31 hsa-miR-1290:PITA hsa-miR-1290:PITA TOP PITA 6.538E-4 8.644E-3
5.969E-2
3.661E-1
 2 353
32 hsa-miR-129-1-3p:TargetScan hsa-miR-129-1-3p TargetScan 6.686E-4 8.644E-3
5.969E-2
3.744E-1
 2 357
33 hsa-miR-129-2-3p:TargetScan hsa-miR-129-2-3p TargetScan 6.686E-4 8.644E-3
5.969E-2
3.744E-1
 2 357
34 CTACCTC,LET-7F:MSigDB CTACCTC,LET-7F:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
35 CTACCTC,LET-7A:MSigDB CTACCTC,LET-7A:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
36 CTACCTC,LET-7C:MSigDB CTACCTC,LET-7C:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
37 CTACCTC,LET-7I:MSigDB CTACCTC,LET-7I:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
38 CTACCTC,LET-7D:MSigDB CTACCTC,LET-7D:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
39 CTACCTC,LET-7E:MSigDB CTACCTC,LET-7E:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
40 CTACCTC,MIR-98:MSigDB CTACCTC,MIR-98:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
41 CTACCTC,LET-7G:MSigDB CTACCTC,LET-7G:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
42 CTACCTC,LET-7B:MSigDB CTACCTC,LET-7B:MSigDB MSigDB 6.873E-4 8.644E-3
5.969E-2
3.849E-1
 2 362
43 hsa-miR-337-5p:mirSVR lowEffct hsa-miR-337-5p:mirSVR nonconserved lowEffect-0.1-0.5 MicroRNA.org 7.101E-4 8.644E-3
5.969E-2
3.976E-1
 2 368
44 hsa-miR-1263:mirSVR highEffct hsa-miR-1263:mirSVR nonconserved highEffect-0.5 MicroRNA.org 7.139E-4 8.644E-3
5.969E-2
3.998E-1
 2 369
45 hsa-miR-1:PITA hsa-miR-1:PITA TOP PITA 7.216E-4 8.644E-3
5.969E-2
4.041E-1
 2 371
46 hsa-miR-206:PITA hsa-miR-206:PITA TOP PITA 7.216E-4 8.644E-3
5.969E-2
4.041E-1
 2 371
47 hsa-miR-613:PITA hsa-miR-613:PITA TOP PITA 7.255E-4 8.644E-3
5.969E-2
4.063E-1
 2 372
48 hsa-let-7d-5p:Functional MTI Functional MTI miRTarbase 8.129E-4 9.484E-3
6.550E-2
4.552E-1
 2 394
49 CTTTGTA,MIR-524:MSigDB CTTTGTA,MIR-524:MSigDB MSigDB 8.754E-4 9.899E-3
6.836E-2
4.902E-1
 2 409
50 hsa-miR-1299:PITA hsa-miR-1299:PITA TOP PITA 8.839E-4 9.899E-3
6.836E-2
4.950E-1
 2 411
Show 45 more annotations

17: Drug [Display Chart] 8 input genes in category / 2909 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 ctd:C004605 butamben CTD 9.258E-14 2.693E-10 2.304E-9 2.693E-10 4 6
2 ctd:C061137 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 CTD 2.035E-12 2.960E-9 2.532E-8 5.921E-9 4 11
3 ctd:C118756 dihydroxy-vitamin D3 CTD 4.409E-12 4.275E-9 3.656E-8 1.283E-8 4 13
4 CID000354654 ferutinin Stitch 1.122E-11 8.158E-9 6.978E-8 3.263E-8 4 16
5 CID000063062 E)-4-hydroxytamoxifen Stitch 2.487E-9 1.447E-6 1.238E-5 7.236E-6 5 197
6 CID006437840 hydroxyethylretinamide Stitch 6.655E-9 3.027E-6 2.589E-5 1.936E-5 4 73
7 CID000003249 vitamin D2 Stitch 7.285E-9 3.027E-6 2.589E-5 2.119E-5 5 244
8 CID000160615 4-hydroxytestosterone Stitch 8.716E-9 3.169E-6 2.711E-5 2.535E-5 4 78
9 CID004568637 AC1ND2OB Stitch 1.102E-8 3.562E-6 3.046E-5 3.205E-5 5 265
10 CID000019390 AC1L2E0P Stitch 2.301E-8 6.692E-6 5.724E-5 6.692E-5 5 307
11 ctd:C041477 3-hydroxyflavone CTD 1.026E-7 2.487E-5 2.127E-4 2.985E-4 3 29
12 CID000104946 LY117018 Stitch 1.026E-7 2.487E-5 2.127E-4 2.985E-4 3 29
13 ctd:D000735 Androstenedione CTD 4.251E-7 9.512E-5 8.135E-4 1.237E-3 3 46
14 ctd:C408047 1,25(OH)2-16-ene-23-yne-26,27-hexafluoro-19-nor-D3 CTD 6.438E-7 1.338E-4 1.144E-3 1.873E-3 2 4
15 ctd:C031324 tris(chloroethyl)phosphate CTD 7.749E-7 1.503E-4 1.285E-3 2.254E-3 3 56
16 ctd:C037032 galangin CTD 1.398E-6 2.542E-4 2.174E-3 4.068E-3 3 68
17 ctd:C104006 2',3',4',5'-tetrachloro-4-biphenylol CTD 1.609E-6 2.600E-4 2.224E-3 4.681E-3 2 6
18 ctd:C040488 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 CTD 1.609E-6 2.600E-4 2.224E-3 4.681E-3 2 6
19 CID000448538 AC1L9M2J Stitch 1.959E-6 2.999E-4 2.565E-3 5.698E-3 3 76
20 ctd:C013320 tris(2-butoxyethyl) phosphate CTD 2.651E-6 3.857E-4 3.299E-3 7.713E-3 3 84
21 CID000005035 raloxifene Stitch 3.655E-6 5.063E-4 4.331E-3 1.063E-2 4 351
22 ctd:C014953 2-acetyltributylcitrate CTD 3.860E-6 5.103E-4 4.365E-3 1.123E-2 2 9
23 CID000091649 hydroxyflutamide Stitch 4.906E-6 6.205E-4 5.307E-3 1.427E-2 3 103
24 CID006914668 AC1OCAFR Stitch 7.072E-6 8.572E-4 7.332E-3 2.057E-2 2 12
25 ctd:D000737 Androstenols CTD 8.357E-6 9.724E-4 8.317E-3 2.431E-2 2 13
26 CID000327967 AC1L71LQ Stitch 1.208E-5 1.338E-3 1.144E-2 3.514E-2 3 139
27 CID000063041 dexamethasone 21-mesylate Stitch 1.285E-5 1.338E-3 1.144E-2 3.738E-2 2 16
28 ctd:C583074 4,4'-hexafluorisopropylidene diphenol CTD 1.288E-5 1.338E-3 1.144E-2 3.746E-2 3 142
29 ctd:C032279 phthalic acid CTD 1.456E-5 1.461E-3 1.249E-2 4.236E-2 2 17
30 CID000166036 androst-2-en-3-ol Stitch 1.638E-5 1.588E-3 1.358E-2 4.764E-2 2 18
31 7535 DN irinotecan HCl; Down 200; 100uM; PC3; HT HG-U133A Broad Institute CMAP Down 2.246E-5 1.947E-3 1.665E-2
6.534E-2
 3 171
32 CID003674064 mobs Stitch 2.471E-5 1.947E-3 1.665E-2
7.188E-2
 2 22
33 6886 DN trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT HG-U133A Broad Institute CMAP Down 2.618E-5 1.947E-3 1.665E-2
7.616E-2
 3 180
34 1791 DN Azaguanine-8 [134-58-7]; Down 200; 26.2uM; PC3; HT HG-U133A Broad Institute CMAP Down 2.662E-5 1.947E-3 1.665E-2
7.743E-2
 3 181
35 CID000331608 NSC325316 Stitch 2.706E-5 1.947E-3 1.665E-2
7.871E-2
 2 23
36 CID000042128 PeCDF Stitch 2.706E-5 1.947E-3 1.665E-2
7.871E-2
 2 23
37 ctd:C045037 testosterone-3-carboxymethyloxime-bovine serum albumin conjugate CTD 2.841E-5 1.947E-3 1.665E-2
8.266E-2
 3 185
38 1043 UP ICI 182,780; Up 200; 1uM; MCF7; HT HG-U133A EA Broad Institute CMAP Up 2.934E-5 1.947E-3 1.665E-2
8.535E-2
 3 187
39 4507 DN Ampyrone [83-07-8]; Down 200; 19.6uM; PC3; HT HG-U133A Broad Institute CMAP Down 3.077E-5 1.947E-3 1.665E-2
8.951E-2
 3 190
40 3379 DN Luteolin [491-70-3]; Down 200; 14uM; MCF7; HT HG-U133A Broad Institute CMAP Down 3.077E-5 1.947E-3 1.665E-2
8.951E-2
 3 190
41 4279 DN Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT HG-U133A Broad Institute CMAP Down 3.224E-5 1.947E-3 1.665E-2
9.379E-2
 3 193
42 1409 DN Etofylline [519-37-9]; Down 200; 17.8uM; HL60; HG-U133A Broad Institute CMAP Down 3.274E-5 1.947E-3 1.665E-2
9.525E-2
 3 194
43 4361 DN Flutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 3.274E-5 1.947E-3 1.665E-2
9.525E-2
 3 194
44 1405 DN Piroxicam [36322-90-4]; Down 200; 12uM; HL60; HG-U133A Broad Institute CMAP Down 3.274E-5 1.947E-3 1.665E-2
9.525E-2
 3 194
45 1156 UP prochlorperazine dimaleate salt; Up 200; 10uM; HL60; HT HG-U133A Broad Institute CMAP Up 3.325E-5 1.947E-3 1.665E-2
9.672E-2
 3 195
46 2468 DN Cetirizine dihydrochloride [83881-52-1]; Down 200; 8.6uM; HL60; HT HG-U133A Broad Institute CMAP Down 3.325E-5 1.947E-3 1.665E-2
9.672E-2
 3 195
47 6994 DN genistein; Down 200; 10uM; MCF7; HT HG-U133A Broad Institute CMAP Down 3.376E-5 1.947E-3 1.665E-2
9.821E-2
 3 196
48 2031 DN Hesperetin [520-33-2]; Down 200; 13.2uM; HL60; HG-U133A Broad Institute CMAP Down 3.376E-5 1.947E-3 1.665E-2
9.821E-2
 3 196
49 1168 UP LY 294002; Up 200; 10uM; HL60; HT HG-U133A Broad Institute CMAP Up 3.376E-5 1.947E-3 1.665E-2
9.821E-2
 3 196
50 3242 UP Carcinine [56897-53-1]; Up 200; 22uM; MCF7; HT HG-U133A Broad Institute CMAP Up 3.428E-5 1.947E-3 1.665E-2
9.971E-2
 3 197
Show 45 more annotations

18: Disease [Display Chart] 8 input genes in category / 108 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 C2940786 Thyroid Hormone Resistance Syndrome DisGeNET Curated 4.692E-7 5.067E-5 2.667E-4 5.067E-5 3 34
2 C0334070 Maturation defect DisGeNET BeFree 3.632E-5 1.961E-3 1.032E-2 3.922E-3 2 19
3 C0206655 Alveolar rhabdomyosarcoma DisGeNET Curated 4.780E-4 8.497E-3 4.473E-2
5.162E-2
 2 68
4 cv:C1839130 Dystonia 3, torsion, X-linked Clinical Variations 4.937E-4 8.497E-3 4.473E-2
5.332E-2
 1 1
5 OMIN:314250 DYSTONIA 3, TORSION, X-LINKED; DYT3 OMIM 4.937E-4 8.497E-3 4.473E-2
5.332E-2
 1 1
6 C4225418 MENTAL RETARDATION, X-LINKED, SYNDROMIC 33 DisGeNET Curated 4.937E-4 8.497E-3 4.473E-2
5.332E-2
 1 1
7 C0014173 Endometrial Hyperplasia DisGeNET Curated 5.507E-4 8.497E-3 4.473E-2
5.948E-2
 2 73
8 C0035412 Rhabdomyosarcoma DisGeNET Curated 7.133E-4 8.951E-3 4.712E-2
7.703E-2
 3 391
9 C0206656 Rhabdomyosarcoma, Embryonal DisGeNET Curated 7.459E-4 8.951E-3 4.712E-2
8.056E-2
 2 85
10 C3642345 Luminal A Breast Carcinoma DisGeNET BeFree 1.245E-3 1.344E-2
7.077E-2
1.344E-1
 2 110
11 C0334616 Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation DisGeNET BeFree 1.480E-3 1.453E-2
7.651E-2
1.599E-1
 1 3
12 C2751067 Parkinsonism-Dystonia, Infantile DisGeNET Curated 1.973E-3 1.639E-2
8.630E-2
2.131E-1
 1 4
13 C0342791 Carnitine-Acylcarnitine Translocase Deficiency DisGeNET Curated 1.973E-3 1.639E-2
8.630E-2
2.131E-1
 1 4
14 C0206643 Neoplasms, Fibrous Tissue DisGeNET BeFree 2.466E-3 1.776E-2
9.347E-2
2.664E-1
 1 5
15 C1266134 Spindle cell rhabdomyosarcoma DisGeNET BeFree 2.466E-3 1.776E-2
9.347E-2
2.664E-1
 1 5
16 C1846868 Favorable response to levodopa DisGeNET Curated 2.959E-3 1.997E-2
1.051E-1
3.196E-1
 1 6
17 C1512981 Mammary Tumorigenesis DisGeNET BeFree 3.181E-3 2.021E-2
1.064E-1
3.436E-1
 2 177
18 C0334342 Skin appendage adenoma DisGeNET BeFree 3.451E-3 2.071E-2
1.090E-1
3.727E-1
 1 7
19 20090226:Yang Treatment response for acute lymphoblastic leukemia GWAS 3.943E-3 2.083E-2
1.096E-1
4.259E-1
 1 8
20 C0553665 Skin endocrine disorder DisGeNET BeFree 4.002E-3 2.083E-2
1.096E-1
4.322E-1
 2 199
21 C1176475 Ductal Carcinoma DisGeNET Curated 4.121E-3 2.083E-2
1.096E-1
4.450E-1
 2 202
22 C0039101 synovial sarcoma DisGeNET Curated 4.363E-3 2.083E-2
1.096E-1
4.712E-1
 2 208
23 C0752210 Dyskinesias, Paroxysmal DisGeNET Curated 4.435E-3 2.083E-2
1.096E-1
4.790E-1
 1 9
24 C0017411 Female Genital Diseases DisGeNET BeFree 4.927E-3 2.129E-2
1.120E-1
5.321E-1
 1 10
25 C0206637 Chondrosarcoma, Mesenchymal DisGeNET Curated 4.927E-3 2.129E-2
1.120E-1
5.321E-1
 1 10
26 C1839130 Dystonia 3, Torsion, X-Linked DisGeNET Curated 5.419E-3 2.251E-2
1.185E-1
5.852E-1
 1 11
27 C0003504 Aortic Valve Insufficiency DisGeNET Curated 5.955E-3 2.382E-2
1.254E-1
6.431E-1
 2 244
28 C0151779 Cutaneous Melanoma DisGeNET Curated 6.243E-3 2.384E-2
1.255E-1
6.742E-1
 2 250
29 C2732473 Ductal Carcinoma In Situ with Microinvasion DisGeNET BeFree 6.401E-3 2.384E-2
1.255E-1
6.913E-1
 1 13
30 C0268301 Reifenstein Syndrome DisGeNET Curated 6.892E-3 2.401E-2
1.264E-1
7.443E-1
 1 14
31 C0302486 Erythrophagocytosis DisGeNET BeFree 6.892E-3 2.401E-2
1.264E-1
7.443E-1
 1 14
32 C0002793 Anaplasia DisGeNET Curated 7.723E-3 2.509E-2
1.321E-1
8.341E-1
 2 279
33 C0007124 Noninfiltrating Intraductal Carcinoma DisGeNET Curated 7.776E-3 2.509E-2
1.321E-1
8.398E-1
 2 280
34 C0023267 Fibroid Tumor DisGeNET Curated 8.212E-3 2.509E-2
1.321E-1
8.869E-1
 2 288
35 C1266119 Solitary fibrous tumor DisGeNET Curated 8.364E-3 2.509E-2
1.321E-1
9.033E-1
 1 17
36 C0013423 Dystonia Musculorum Deformans DisGeNET Curated 8.364E-3 2.509E-2
1.321E-1
9.033E-1
 1 17
37 C2826025 Mixed phenotype acute leukemia DisGeNET BeFree 8.854E-3 2.523E-2
1.328E-1
9.562E-1
 1 18
38 C0862506 Borderline ovarian tumour DisGeNET BeFree 9.343E-3 2.523E-2
1.328E-1
1.000E0
 1 19
39 C0344460 Carcinoma ex pleomorphic adenoma DisGeNET BeFree 9.343E-3 2.523E-2
1.328E-1
1.000E0
 1 19
40 C1334015 High Grade Intraepithelial Neoplasia DisGeNET BeFree 9.343E-3 2.523E-2
1.328E-1
1.000E0
 1 19
41 C3149841 POLYCYSTIC KIDNEY DISEASE 1 DisGeNET Curated 1.130E-2 2.887E-2
1.520E-1
1.000E0
 1 23
42 C0752203 Dystonia, Primary DisGeNET BeFree 1.130E-2 2.887E-2
1.520E-1
1.000E0
 1 23
43 C0042133 Uterine Fibroids DisGeNET Curated 1.150E-2 2.887E-2
1.520E-1
1.000E0
 2 343
44 C0206731 Angiofibroma DisGeNET Curated 1.228E-2 3.014E-2
1.586E-1
1.000E0
 1 25
45 C4020858 Choreatic disease DisGeNET Curated 1.374E-2 3.298E-2
1.736E-1
1.000E0
 1 28
46 C0032300 Lobar Pneumonia DisGeNET BeFree 1.472E-2 3.455E-2
1.819E-1
1.000E0
 1 30
47 C0741899 Poorly differentiated carcinoma DisGeNET BeFree 1.569E-2 3.495E-2
1.840E-1
1.000E0
 1 32
48 C0004135 Ataxia Telangiectasia DisGeNET Curated 1.594E-2 3.495E-2
1.840E-1
1.000E0
 2 407
49 C0410207 Tubular Aggregate Myopathy DisGeNET Curated 1.618E-2 3.495E-2
1.840E-1
1.000E0
 1 33
50 C0023464 Acute biphenotypic leukemia DisGeNET Curated 1.618E-2 3.495E-2
1.840E-1
1.000E0
 1 33
Show 45 more annotations